Telomerase as a universal tumor antigen for cancer vaccines

References

• Van Pel A, van der Bruggen P, Coulie P et al. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev.145, 229–250 (1995).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today18, 175–182 (1997).
   PubMedGoogle Scholar
• Van Pel A, van der Bruggen P, Coulie PG et al. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev.145, 229–250 (1995).
   PubMed Web of Science ®Google Scholar
• Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr. Opin. Immunol.9, 684–693 (1997).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature411, 380–384 (2001).
   PubMed Web of Science ®Google Scholar
• Van Der Bruggen P, Zhang Y, Chaux P et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev.188, 51–64 (2002).
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu. Rev. Immunol.22, 329–360 (2004).
   PubMed Web of Science ®Google Scholar
• Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN γ receptors. Immunity1, 447–456 (1994).
   PubMed Web of Science ®Google Scholar
• van den Broek ME, Kagi D, Ossendorp F et al. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med.184, 1781–1790 (1996).
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Shankaran V, Dighe AS et al. Demonstration of an interferon g-dependent tumor surveillance system in immunocompetent mice. Proc. Natl Acad. Sci. USA95, 7556–7561 (1998).
   PubMed Web of Science ®Google Scholar
• Shankaran V, Ikeda H, Bruce AT et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature410, 1107–1111 (2001).
   PubMed Web of Science ®Google Scholar
• Clark WH Jr, Elder DE, Guerry DT et al. Model predicting survival in stage I melanoma based on tumor progression. J. Natl. Cancer Inst.81, 1893–1904 (1989).
   PubMed Web of Science ®Google Scholar
• Marrogi AJ, Munshi A, Merogi AJ et al. Study of tumor infiltrating lymphocytes and transforming growth factor-β as prognostic factors in breast carcinoma. Int. J. Cancer74, 492–501 (1997).
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med.348, 201–211 (2003).
   Google Scholar
• Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med.353, 2654–2666 (2005).
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science313, 1960–1964 (2006).
   PubMed Web of Science ®Google Scholar
• Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother.54, 187–207 (2005).
   PubMed Web of Science ®Google Scholar
• Jager E, Ringhoffer M, Karbach J et al. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer66, 470–476 (1996).
   PubMed Web of Science ®Google Scholar
• Yee C, Thompson JA, Roche P et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med.192, 1637–1644 (2000).
   PubMed Web of Science ®Google Scholar
• Schmollinger JC, Vonderheide RH, Hoar KM et al. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc. Natl Acad. Sci. USA100, 3398–3403 (2003).
   Google Scholar
• Schultze JL, Vonderheide RH. From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol.22, 516–523 (2001).
   PubMed Web of Science ®Google Scholar
• Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene21, 674–679 (2002).
   PubMed Web of Science ®Google Scholar
• Vonderheide RH. Prospects and challenges of building a cancer vaccine targeting telomerase. Biochimie90, 173–180 (2008).
   PubMedGoogle Scholar
• Gordan JD, Vonderheide RH. Universal tumor antigens as targets for immunotherapy. Cytotherapy4, 317–327 (2002).
   PubMed Web of Science ®Google Scholar
• Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol. Mol. Biol. Rev.66, 407–425 (2002).
   PubMed Web of Science ®Google Scholar
• Hahn WC, Meyerson M. Telomerase activation, cellular immortalization and cancer. Ann. Med.33, 123–129 (2001).
   PubMed Web of Science ®Google Scholar
• Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell2, 257–265 (2002).
   PubMed Web of Science ®Google Scholar
• Blackburn EH. Switching and signaling at the telomere. Cell106, 661–673 (2001).
   PubMed Web of Science ®Google Scholar
• Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science266, 2011–2015 (1994).
   PubMed Web of Science ®Google Scholar
• Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature345, 458–460 (1990).
   PubMed Web of Science ®Google Scholar
• Hastie ND, Dempster M, Dunlop MG et al. Telomere reduction in human colorectal carcinoma and with ageing. Nature346, 866–868 (1990).
   PubMed Web of Science ®Google Scholar
• Meyerson M, Counter CM, Eaton EN et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell90, 785–795 (1997).
   PubMed Web of Science ®Google Scholar
• Nakamura TM, Morin GB, Chapman KB et al. Telomerase catalytic subunit homologs from fission yeast and human. Science277, 955–959 (1997).
   PubMed Web of Science ®Google Scholar
• Counter CM, Botelho FM, Wang P, Harley CB, Bacchetti S. Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein–Barr virus-transformed human B lymphocytes. J. Virol.68, 3410–3414 (1994).
   PubMed Web of Science ®Google Scholar
• Bodnar AG, Ouellette M, Frolkis M et al. Extension of life-span by introduction of telomerase into normal human cells. Science279, 349–352 (1998).
   PubMed Web of Science ®Google Scholar
• Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol.8, 279–282 (1998).
   PubMed Web of Science ®Google Scholar
• Hahn WC, Counter CM, Lundberg AS et al. Creation of human tumour cells with defined genetic elements. Nature400, 464–468 (1999).
   PubMed Web of Science ®Google Scholar
• Hahn WC, Stewart SA, Brooks MW et al. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med.5, 1164–1170 (1999).
   PubMed Web of Science ®Google Scholar
• Herbert B, Pitts AE, Baker SI et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl Acad. Sci. USA96, 14276–14281 (1999).
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity10, 673–679 (1999).
   PubMed Web of Science ®Google Scholar
• Minev B, Hipp J, Firat H et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc. Natl Acad. Sci. USA97, 4796–4801 (2000).
   PubMed Web of Science ®Google Scholar
• Dupont J, Latouche JB, Ma C, Sadelain M. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res.65, 5417–5427 (2005).
   PubMed Web of Science ®Google Scholar
• Filaci G, Fravega M, Setti M et al. Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer. Blood107, 1505–1512 (2006).
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Riley JP, Igarashi T et al. Immunization of patients with the hTERT:540–548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin. Cancer Res.10, 4688–4698 (2004).
   PubMed Web of Science ®Google Scholar
• Ayyoub M, Migliaccio M, Guillaume P et al. Lack of tumor recognition by hTERT peptide 540–548-specific CD8+ T cells from melanoma patients reveals inefficient antigen processing. Eur. J. Immunol.31, 2642–2651 (2001).
   PubMed Web of Science ®Google Scholar
• Wenandy L, Sorensen RB, Sengelov L et al. The immunogenicity of the hTERT540–548 peptide in cancer. Clin. Cancer Res.14, 4–7 (2008).
   PubMedGoogle Scholar
• Nair SK, Heiser A, Boczkowski D et al. Induction of cytotoxic T lymphocyte responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat. Med.6, 1011–1017 (2000).
   PubMed Web of Science ®Google Scholar
• Gross DA, Graff-Dubois S, Opolon P et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J. Clin. Invest.113, 425–433 (2004).
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Schultze JL, Anderson KS et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res.61, 8366–8370 (2001).
   PubMed Web of Science ®Google Scholar
• Gannage M, Abel M, Michallet AS et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J. Immunol.174, 8210–8218 (2005).
   PubMed Web of Science ®Google Scholar
• Domchek SM, Recio A, Mick R et al. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res.67, 10546–10555 (2007).
   PubMed Web of Science ®Google Scholar
• Maecker B, von Bergwelt-Baildon MS, Anderson KS et al. Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients. Clin. Exp. Immunol.141, 558–562 (2005).
   PubMed Web of Science ®Google Scholar
• Danet-Desnoyers G, Luongo J, Bonnet D, Domchek S, Vonderheide R, Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. Exp. Hematology33, 1275–1280 (2005).
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Yang BK et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J. Immunol.174, 3798–3807 (2005).
   PubMed Web of Science ®Google Scholar
• Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv. Immunol.90, 51–81 (2006).
   PubMed Web of Science ®Google Scholar
• Finke LH, Wentworth K, Blumenstein B et al. Lessons from randomized Phase III studies with active cancer immunotherapies – outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine25(Suppl. 2), B97–B109 (2007).
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention. Discov. Med.7, 103–108 (2007).
   Google Scholar
• Vonderheide RH, Domchek SM, Schultze JL et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin. Cancer Res.10, 828–839 (2004).
   PubMed Web of Science ®Google Scholar
• Brunsvig PF, Aamdal S, Gjertsen MK et al. Telomerase peptide vaccination: a Phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother.55, 1553–1564 (2006).
   PubMed Web of Science ®Google Scholar
• Bernhardt SL, Gjertsen MK, Trachsel S et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating Phase I/II study. Br. J. Cancer95, 1474–1482 (2006).
   PubMed Web of Science ®Google Scholar
• Mavroudis D, Bolonakis I, Cornet S et al. A Phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies. Oncology70, 306–314 (2006).
   PubMed Web of Science ®Google Scholar
• Bolonaki I, Kotsakis A, Papadimitraki E et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J. Clin. Oncol.25, 2727–2734 (2007).
   PubMed Web of Science ®Google Scholar
• Cortez-Gonzalez X, Zanetti M. Telomerase immunity from bench to bedside: round one. J. Transl. Med.5, 12 (2007).
   PubMed Web of Science ®Google Scholar